Amphastar Pharmaceuticals, Inc. or Travere Therapeutics, Inc.: Who Leads in Yearly Revenue?

Amphastar's Revenue Dominance Over Travere: A Decade in Review

__timestampAmphastar Pharmaceuticals, Inc.Travere Therapeutics, Inc.
Wednesday, January 1, 201421046100028203205
Thursday, January 1, 201525151900099892000
Friday, January 1, 2016255165000133591000
Sunday, January 1, 2017240175000154937000
Monday, January 1, 2018294666000164246000
Tuesday, January 1, 2019322357000175338000
Wednesday, January 1, 2020349846000198321000
Friday, January 1, 2021437768000227490000
Saturday, January 1, 2022498987000212018000
Sunday, January 1, 2023644395000145238000
Loading chart...

Unleashing the power of data

Amphastar vs. Travere: A Revenue Showdown

In the competitive landscape of pharmaceuticals, revenue growth is a key indicator of success. Over the past decade, Amphastar Pharmaceuticals, Inc. has consistently outperformed Travere Therapeutics, Inc. in annual revenue. Starting in 2014, Amphastar's revenue was nearly 7.5 times that of Travere's. By 2023, Amphastar's revenue surged by over 200%, reaching a peak that is more than four times Travere's earnings.

A Decade of Growth

Amphastar's revenue trajectory shows a steady climb, with a notable 30% increase from 2021 to 2023. In contrast, Travere's revenue peaked in 2021 but saw a decline by 2023. This trend highlights Amphastar's robust market strategy and adaptability in a dynamic industry.

The Future Outlook

As we look to the future, Amphastar's consistent growth positions it as a leader in the pharmaceutical sector, while Travere may need to innovate to close the revenue gap.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025